What is Compugen?
Compugen operates at the forefront of therapeutic discovery and development, leveraging its proprietary computational platforms to identify and validate novel drug targets. The company's core mission is to translate these discoveries into innovative therapeutics, with a primary focus on the critical field of cancer immunotherapy. By employing predictive computational discovery, Compugen aims to accelerate the identification of promising therapeutic candidates, thereby streamlining the drug development pipeline and addressing unmet medical needs in oncology.
How much funding has Compugen raised?
Compugen has raised a total of $71M across 2 funding rounds:
Stock Offering
$51M
Stock Offering
$20M
Stock Issuance/Offering (2014): $51M, investors not publicly disclosed
Stock Issuance/Offering (2021): $20M led by Bristol-Myers Squibb
Key Investors in Compugen
Bristol-Myers Squibb
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer.
What's next for Compugen?
The recent major strategic investment signals a pivotal moment for Compugen, likely enabling the company to accelerate its preclinical and clinical development programs. This influx of capital is expected to fuel further research into its identified drug targets and advance its therapeutic candidates through rigorous testing phases. The company's focus on cancer immunotherapy positions it within a rapidly evolving and high-demand sector of the pharmaceutical industry, suggesting a strategic push towards expanding its pipeline and potentially forging new partnerships to bring its innovative treatments to patients.
See full Compugen company page
